With our collaboration partner Roche Genentech, we are developing TransCon Ranibizumab for the treatment of Age-related Macular Edema (AMD) and other ophthalmic indications. TransCon Ranibizumab is a novel prodrug designed to support up to half-yearly administration frequencies, and to provide the same or improved efficacy compared to current intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.
TransCon technology may provide a unique opportunity to reduce the frequency of highly invasive intravitreal injections while enabling the release of an active parent drug from our TransCon carrier system. We believe our TransCon technology may enable intravitreal delivery of a variety of molecules, including small molecules, peptides and proteins.
Roche Genentech is currently conducting preclinical studies to evaluate the safety and efficacy of various TransCon prodrug candidates for intravitreal administration.
Ophthalmic diseases, including neovascular wet AMD, macular edema following retinal vein occlusion and diabetic macular edema, are serious sight-threatening diseases. Without treatment, most patients experience progressive and inevitable vision loss. Anti-VEGF therapies have been transformative in the treatment of these diseases, resulting in patients routinely gaining back significant vision for several years. Lucentis® (ranibizumab) is a leading anti-VEGF drug, and is administered as periodic intravitreal injections. Due to the invasiveness of frequent intravitreal injections, there is a significant unmet medical need for longer acting anti-VEGF therapy.